{"url_path":"/sec/gwll/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1800373/0001477932-26-004130-index.html","accession_number":"0001477932-26-004130","cik":"0001800373","ticker":"GWLL","issuer_name":"GOLDENWELL BIOTECH, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1800373/0001477932-26-004130-index.html","primary_entity_key":"0001800373","primary_entity_name":"GOLDENWELL BIOTECH, INC."},"word_count":1168,"has_tables":true,"body_markdown":"gdwl_10k.htm\n0001800373false--12-31FY2025truefalsefalse0.00013000000009900000099000000990000000.000.000.000.00falsefalsefalsefalse276152761500018003732025-01-012025-12-310001800373gdwl:FounderMember2019-12-310001800373gdwl:FounderMember2021-01-012021-01-110001800373gdwl:FounderMember2019-08-012019-08-2000018003732022-11-012022-11-0900018003732020-11-282020-12-0100018003732021-01-012021-01-1100018003732021-02-012021-02-2200018003732019-08-012019-08-200001800373gdwl:TreasurerMember2021-06-070001800373gdwl:AustralianTrefoilHeathTechnologyMember2021-06-052021-06-070001800373us-gaap:RetainedEarningsMember2025-12-310001800373gdwl:SubscriptionReceivableMember2025-12-310001800373us-gaap:AdditionalPaidInCapitalMember2025-12-310001800373us-gaap:CommonStockMember2025-12-310001800373us-gaap:RetainedEarningsMember2025-10-012025-12-310001800373gdwl:SubscriptionReceivableMember2025-10-012025-12-3100018003732025-09-300001800373us-gaap:RetainedEarningsMember2025-09-300001800373us-gaap:AdditionalPaidInCapitalMember2025-09-300001800373us-gaap:CommonStockMember2025-09-3000018003732025-07-012025-09-300001800373us-gaap:RetainedEarningsMember2025-07-012025-09-300001800373gdwl:SubscriptionReceivableMember2025-07-012025-09-300001800373us-gaap:RetainedEarningsMember2025-06-300001800373us-gaap:AdditionalPaidInCapitalMember2025-06-300001800373us-gaap:CommonStockMember2025-06-3000018003732025-04-012025-06-300001800373us-gaap:RetainedEarningsMember2025-04-012025-06-300001800373gdwl:SubscriptionReceivableMember2025-04-012025-06-3000018003732025-03-310001800373us-gaap:RetainedEarningsMember2025-03-310001800373us-gaap:AdditionalPaidInCapitalMember2025-03-310001800373us-gaap:CommonStockMember2025-03-3100018003732025-01-012025-03-310001800373us-gaap:RetainedEarningsMember2025-01-012025-03-310001800373gdwl:SubscriptionReceivableMember2025-01-012025-03-310001800373us-gaap:RetainedEarningsMember2024-12-310001800373us-gaap:AdditionalPaidInCapitalMember2024-12-310001800373us-gaap:CommonStockMember2024-12-310001800373us-gaap:RetainedEarningsMember2024-10-012024-12-310001800373gdwl:SubscriptionReceivableMember2024-10-012024-12-3100018003732024-09-300001800373us-gaap:RetainedEarningsMember2024-09-300001800373us-gaap:AdditionalPaidInCapitalMember2024-09-300001800373us-gaap:CommonStockMember2024-09-3000018003732024-07-012024-09-300001800373us-gaap:RetainedEarningsMember2024-07-012024-09-300001800373gdwl:SubscriptionReceivableMember2024-07-012024-09-3000018003732024-06-300001800373us-gaap:RetainedEarningsMember2024-06-300001800373us-gaap:AdditionalPaidInCapitalMember2024-06-300001800373us-gaap:CommonStockMember2024-06-3000018003732024-04-012024-06-300001800373us-gaap:RetainedEarningsMember2024-04-012024-06-300001800373gdwl:SubscriptionReceivableMember2024-04-012024-06-3000018003732024-03-310001800373us-gaap:RetainedEarningsMember2024-03-310001800373us-gaap:AdditionalPaidInCapitalMember2024-03-310001800373us-gaap:CommonStockMember2024-03-3100018003732024-01-012024-03-310001800373us-gaap:RetainedEarningsMember2024-01-012024-03-310001800373gdwl:SubscriptionReceivableMember2024-01-012024-03-3100018003732023-12-310001800373us-gaap:RetainedEarningsMember2023-12-310001800373us-gaap:AdditionalPaidInCapitalMember2023-12-310001800373us-gaap:CommonStockMember2023-12-3100018003732024-01-012024-12-3100018003732024-10-012024-12-3100018003732025-10-012025-12-3100018003732024-12-3100018003732025-12-3100018003732026-05-2800018003732025-06-30iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n**FORM 10-K**\n\n \n\n**ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF**\n\n**THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the fiscal year ended **December 31, 2025**\n\n \n\nCommission File No. **000-56275**\n\n \n\n**GOLDENWELL BIOTECH, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Nevada**\n\n**84-2896086**\n\n(State or other jurisdiction of\n\n(I.R.S. Employer\n\nincorporation or organization)\n\nIdentification No.)\n\n \n\n**7316 Capilano Dr.**\n\n**Solon, Ohio 44139**\n\n(Address of principal executive offices, zip code)\n\n \n\n**(440) 666-7999**\n\n(Registrant’s telephone number, including area code)\n\n \n\n(Former name, former address and former fiscal year, if changed since last report)\n\n \n\n**Securities registered pursuant to Section 12(b) of the Act:**\n\n \n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\n \n\n \n\n \n\n \n\n**SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:**\n\n \n\n**Common Stock, $.001 Par Value**\n\n \n\nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐     No ☒\n\n \n\nIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐     No ☒\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer   \n\n☐\n\nAccelerated filer \n\n☐\n\nNon-accelerated Filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\n \n\nEmerging growth company \n\n☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒\n\n \n\nIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐     No ☒\n\n \n\nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐\n\n \n\nIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐\n\n \n\nAt June 30, 2025, the last business day of the Registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting common stock held by non-affiliates of the Registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) was approximately $14,520,000. \n\n \n\nAs of May 28, 2026 there were 99,000,000 shares of the Registrant’s common stock, par value $0.001 per share, outstanding.\n\n \n\n \n\n \n\n \n\n**GOLDENWELL BIOTECH, INC.**\n\n**TABLE OF CONTENTS**\n\n \n\n \n\n \n\n \n\n**Page No.**\n\n \n\n**PART I**\n\n \n\n \n\n \n\n \n\n \n\n[Item 1.](#i1)\n\n[Business.](#i1)\n\n \n\n \n\n3\n\n \n\n[Item 1A.](#i1a)\n\n[Risk Factors.](#i1a)\n\n \n\n \n\n9\n\n \n\n[Item 1B.](#i1b)\n\n[Unresolved Staff Comments.](#i1b)\n\n \n\n \n\n9\n\n \n\n[Item1C.](#i1c)\n\n[Cybersecurity.](#i1c)\n\n \n\n \n\n9\n\n \n\n[Item 2.](#i2)\n\n[Properties.](#i2)\n\n \n\n \n\n10\n\n \n\n[Item 3.](#i3)\n\n[Legal Proceedings.](#i3)\n\n \n\n \n\n10\n\n \n\n[Item 4.](#i4)\n\n[Mine Safety Disclosures.](#i4)\n\n \n\n \n\n10\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**PART II**\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 5.](#i5)\n\n[Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.](#i5)\n\n \n\n \n\n11\n\n \n\n[Item 6.](#i6)\n\n[[Reserved]](#i6)\n\n \n\n \n\n11\n\n \n\n[Item 7.](#i7)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations.](#i7)\n\n \n\n \n\n11\n\n \n\n[Item 7A.](#i7a)\n\n[Quantitative and Qualitative Disclosures About Market Risk.](#i7a)\n\n \n\n \n\n15\n\n \n\n[Item 8.](#i8)\n\n[Financial Statements and Supplementary Data.](#i8)\n\n \n\n \n\n16\n\n \n\n[Item 9.](#i9)\n\n[Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.](#i9)\n\n \n\n \n\n17\n\n \n\n[Item 9A.](#i9a)\n\n[Controls and Procedures.](#i9a)\n\n \n\n \n\n17\n\n \n\n[Item 9B.](#i9b)\n\n[Other Information.](#i9b)\n\n \n\n \n\n18\n\n \n\n[Item 9C.](#i9c)\n\n[Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.](#i9c)\n\n \n\n \n\n18\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**PART III**\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 10.](#i10)\n\n[Directors, Executive Officers and Corporate Governance.](#i10)\n\n \n\n \n\n19\n\n \n\n[Item 11.](#i11)\n\n[Executive Compensation.](#i11)\n\n \n\n \n\n22\n\n \n\n[Item 12.](#i12)\n\n[Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.](#i12)\n\n \n\n \n\n25\n\n \n\n[Item 13.](#i13)\n\n[Certain Relationships and Related Transactions, and Director Independence.](#i13)\n\n \n\n \n\n25\n\n \n\n[Item 14.](#i14)\n\n[Principal Accounting Fees and Services.](#i14)\n\n \n\n \n\n26\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**PART IV**\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Item 15.](#i15)\n\n[Exhibits and Financial Statement Schedules.](#i15)\n\n \n\n \n\n27\n\n \n\n[Item 16.](#i16)\n\n[Form 10-K Summary.](#i16)\n\n \n\n \n\n27\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n[Signatures](#sign)\n\n \n\n \n\n28\n\n \n\n \n\n \n\n2\n\n*Table of Contents*\n\n \n\n**FORWARD-LOOKING STATEMENTS**\n\n \n\nThis Annual Report on Form 10-K of Goldenwell Biotech, Inc., a Nevada corporation (the “Company”), contains “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “could”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: (i) commercialization of our technology and products, (ii) development and protection of our intellectual property, (iii) the Company’s need for and ability to obtain additional financing, (iv) industry competition, (v) other factors over which we have little or no control; and (vi) other factors discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”).\n\n \n\nOur management has included projections and estimates in this Form 10-K, which are based primarily on management’s experience in the industry, assessments of our results of operations, discussions and negotiations with third parties and a review of information filed by our competitors with the SEC or otherwise publicly available. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.\n\n \n\n**PART I**"}